Lam-002a
Tīmeklis2024. gada 28. jūl. · LAM-002A has already proven to be safe in previous clinical trials for the treatment for autoimmune diseases and follicular lymphoma, according to the researchers. To identify the drug, researchers used AI algorithms to screen more than 13,000 existing drugs against two strains of the live SARS-CoV-2 virus. Tīmeklis2024. gada 8. marts · Other Clinical Trials. PA15-0575 Observational prospective Research study In monoclonal Gammopathies leadINg to myeloma (ORIGIN study) 2024-1088 A Multicenter, Open-label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma with or without HIV.
Lam-002a
Did you know?
Tīmeklis2024. gada 27. jūl. · LAM-002A is a first in class, highly selective PIKfyve kinase inhibitor 1,2 that has demonstrated potent in vitro antiviral activity against several … Tīmeklis2024. gada 27. jūl. · US biotech AI Therapeutics has begun a phase 2 trial of its LAM-002A, an antiviral drug that has shown promise against the SARS-CoV-2 coronavirus in the lab. The company develops drugs that...
TīmeklisAI Therapeutics has initiated a clinical trial of LAM-002A, the current formulation in the AIT-101 program, in ALS patients with a C9orf72 mutation (C9ALS) to evaluate safety, tolerability, blood brain barrier (BBB) penetration, and impact on target and disease biomarkers as well as functional parameters. The C9ALS subpopulation was chosen … Tīmeklis2024. gada 27. jūl. · LAM-002A is a first in class, highly selective PIKfyve kinase inhibitor 1,2 that has demonstrated potent in vitro antiviral activity against several isolates of SARS-CoV-2, the virus responsible...
Tīmeklis2016. gada 26. febr. · LAM-002A is an oral selective kinase inhibitor currently undergoing Phase I trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. These trials seek to evaluate the safety, tolerability, and … Tīmeklis2024. gada 25. maijs · Background: LAM-002 is a selective inhibitor of PIKfyve that disrupts lysosomal homeostasis, inducing cytotoxicity in B-cell lymphoma models as …
Tīmeklis2024. gada 30. janv. · LAM-002 (apilimod) is an inhibitor of the PIKfyve kinase that works by clearing toxic protein aggregates, or clumps, within lysosomes — cell compartments in which unwanted molecules are broken down or digested. Abnormal lysosomal function is commonly observed in neurodegenerative diseases like …
goods crooked linesTīmeklisApplication: Shrouded, polarized self-mating system for rugged applications up to 60 pins. Contact System: Tiger Buy™. Orientation: Vertical, right-angle. Pitch: 2.00 mm … good scrub brandsTīmeklis2015. gada 3. nov. · LAM-002A is supplied as 25-mg or 50-mg capsules and will be administered two times daily or three times daily by mouth in repeated 28-day cycles. … goods cum passenger vehicleTīmeklis*LAM-002A is the current formulation being studied in the AIT-101 program To learn more, click here to visit ClinicalTrials.gov. (ClinicalTrials.gov Identifier: … good scrum team namesTīmeklis2024. gada 6. apr. · The Phase 2a clinical trial was conducted with the current formulation of AIT-101, also known as LAM-002A. Additional information is available at www.clinicaltrials.gov (NCT05163886). About AIT-101 . AIT-101 is a first-in-class, potent and highly selective inhibitor of the lipid kinase PIKfyve. Inhibition of PIKfyve leads to … goods cum passenger liftTīmeklis2024. gada 27. dec. · Abstract. The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent … good scrum master resumeTīmeklis2024. gada 27. jūl. · LAM-002A is a first in class, highly selective PIKfyve kinase inhibitor 1,2 that has demonstrated potent in vitro antiviral activity against several … good scrum master qualities